Prothena Announces Presentation of Clinical Data From the Ongoing Phase 1/2 NEOD001 Study and Systemic Amyloidosis Patient Survey Results

Prothena Corporation plc

, a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke will give an oral presentation of clinical data from its ongoing Phase 1/2 trial of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction at the 20th Congress of the European Hematology Association (EHA) to be held June 11 – 14, 2015 in Vienna, Austria. In addition, the Amyloidosis Research Consortium will present results from a survey of patients with systemic amyloidosis conducted in collaboration with Prothena. The presentation sessions can be accessed as follows: (Abstract #S104) Phase 1/2 study of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction Presenter: Michaela Liedtke, MD, Stanford University School of Medicine Topic: Myeloma and Other Monoclonal Gammopathies - Clinical Session: Multiple Myeloma: Clinical Studies 1 Date and Time: Friday, June 12, 12:15 – 12:30 p.m. CET Location: Room A2+3 Data contained in the published abstract was current as of September 30, 2014. Updated clinical data from the ongoing Phase 1/2 trial of NEOD001 will be presented at EHA. (Abstract # E1262) Patient Experience with Light Chain Amyloidosis: A Survey from the Amyloidosis Research Consortium Presenter: Isabelle Lousada, Amyloidosis Research Consortium, Inc. Topic: Myeloma and Other Monoclonal Gammopathies - Clinical Date and Time: Friday, June 12, 9:30 a.m. to Saturday, June 13, 6:45 p.m. CET Location: E-poster screens